Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PT-112 in advanced solid tumors and mCRPC
NCT02266745Phase 2Active, not recruiting
- Sponsor
- Promontory Therapeutics
- Start
- Jul 2014
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label trial of Imifoplatin in solid tumor, thymoma, thymic carcinoma (TC) and 1 more (3 arms), sponsored by Promontory Therapeutics. Primary endpoints: Maximum Tolerated Dose and Recommended Phase 2 Dose. Started Jul 2014; status: active, not recruiting.
02
Drugs
Imifoplatin
03
Conditions
solid tumorthymomathymic carcinoma (TC)prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02266745.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02266745.